A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
Key facts
- Where
- A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, and Valencia, SpainSee the 13 sites
- Phase
- Phase 1
Where in Spain
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Institut Catala d'OncologiaBadalona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Clinica Universidad de NavarraMadrid, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
- Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines Inc.
- Trial code
- EU 2023-509572-42-00
- Record updated
- 22 September 2026
- Original description
To evaluate the safety and tolerability of daraxonrasib in combination with pembrolizumab, with or without chemotherapy, in patients with advanced RAS- mutated NSCLCRead full original descriptionShow less
A Phase 1b/2 Open-Label, Multicenter Study of Daraxonrasib (RMC-6236) in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
To evaluate the safety and tolerability of daraxonrasib in combination with pembrolizumab, with or without chemotherapy, in patients with advanced RAS- mutated NSCLC
Inclusion: Patients that are at least 18 years old or legal age of consent Patients that have NSCLC with certain RAS mutations. Patients that have NSCLC that is unlikely to be cured and has grown or spread to other body parts. Patients that have received prior cancer treatment, are not suitable for standard treatments, or no standard treatments are available.. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. Patients that have adequate organ function (bone marrow, liver, kidney).
Exclusion: Participants that have primary brain and spinal cord tumor spreading to other body parts. 2. Participants that have gastrointestinal problems that may affect absorption of daraxonrasib. 3. Participants that had any major surgery in the last 4 weeks. 4. Participants that have have previously taken targeted therapy for RAS mutation. 5. Participants that have any other medical condition that may interfere with the study drugs. 6. Participants that need other medicines, treatments or eating foods that may interfere with study drugs.